New cancer drug INCA32459 enters early human testing

NCT ID NCT05577182

Completed Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new drug called INCA32459 in 46 people with advanced cancers that had spread. The main goals were to check safety, find the right dose, and see how the body handles the drug. It is too early to know if the drug works, but the results will guide future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INCA32459
What this could lead to: If successful, this could point toward a new treatment option for certain advanced cancers.
What could go wrong: This is a very early Phase 1 trial with only 46 people, focused on safety and dosing. It is too soon to know if the drug works, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer head and neck squamous cell carcinoma melanoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANCIES

Contacts and locations

Locations

Centro Integral Oncologico Clara Campal

Madrid, 28050, Spain
Centro Ricerche Cliniche Di Verona (Crc)

Verona, 37134, Italy
Chu Ucl Namur University Hospital Mont-Godinne

Yvoir, 05530, Belgium
Cliniques Universitaires Ucl Saint-Luc

Brussels, 01200, Belgium
Hospital Quironsalud Barcelona

Barcelona, 08023, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario Quironsalud Madrid

Pozuelo de Alarcón, 28223, Spain
Ico Institut Catala D Oncologia

L'Hospitalet de Llobregat, 08906, Spain
The Angeles Clinic and Research Institute

Los Angeles, California, 90025, United States
Universitair Ziekenhuis Antwerpen (Uza)

Edegem, 02650, Belgium
Universitair Ziekenhuis Brussel

Jette, 01090, Belgium
Universitair Ziekenhuis Gent

Ghent, 09000, Belgium
University of Texas Md Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.